内容紹介
Study of Tolerability of Capecitabine in Postoperative Adjuvant Chemotherapy in Colon Cancer
Summary
Objective: Based on the results of the X-ACT study, capecitabine has become one of the standard postoperative adjuvant chemotherapies for colon cancer. However, few studies of tolerability have been conducted in Japan. Method: In this study, we retrospectively examined treatment continuation, and the adverse events that occurred during eight courses of postoperative adjuvant chemotherapy with capecitabine, in 34 patients with colon cancer who had undergone curative resection. Result: The completion rate for eight courses of treatment with capecitabine was 79.4%(27 of 34 subjects), the median relative dose intensity was 94.4%(13% to 106%), and the proportion of subjects with relative dose intensity ≤ 60% was 82.4%(28 of 34 subjects). The following Grade 3 or higher adverse events were reported: hand-foot syndrome, in 11.8%(4 of 34 subjects); mucositis oral, in 2.9%(1 of 34 subjects); diarrhea, in 2.9%(1 of 34 subjects); and glans penis ulcer, in 2.9%(1 of 34 subjects). Conclusion: In our hospital, a high rate of capecitabine treatment continuation comparable to that reported in the X-ACT study was obtained, suggesting that capecitabine adjuvant chemotherapy would be well tolerated in clinical practice as well.
要旨
目的: capecitabineはX-ACT試験の結果から結腸癌術後補助化学療法の標準治療の一つとなったが,本邦では忍容性についての報告はほとんどない。今回,治癒切除が行われた結腸癌34例を対象として,capecitabineによる術後補助化学療法8コースの治療継続性や有害事象について後方視的に検討した。結果: capecitabineの8コース完遂率79.4%(27/34例),相対用量強度中央値94.4(13～106)%,相対用量強度60%以上の割合82.4%(28/34例)であり,Grade 3以上の有害事象は手足症候群11.8%(4/34例),口腔粘膜炎2.9%(1/34例),下痢2.9%(1/34例),亀頭部潰瘍2.9%(1/34例)であった。結語: 当院におけるcapecitabineはX-ACT試験と同等の高い治療継続性が得られており,日常診療においても忍容性が高いと考えられた。
目次
Summary
Objective: Based on the results of the X-ACT study, capecitabine has become one of the standard postoperative adjuvant chemotherapies for colon cancer. However, few studies of tolerability have been conducted in Japan. Method: In this study, we retrospectively examined treatment continuation, and the adverse events that occurred during eight courses of postoperative adjuvant chemotherapy with capecitabine, in 34 patients with colon cancer who had undergone curative resection. Result: The completion rate for eight courses of treatment with capecitabine was 79.4%(27 of 34 subjects), the median relative dose intensity was 94.4%(13% to 106%), and the proportion of subjects with relative dose intensity ≤ 60% was 82.4%(28 of 34 subjects). The following Grade 3 or higher adverse events were reported: hand-foot syndrome, in 11.8%(4 of 34 subjects); mucositis oral, in 2.9%(1 of 34 subjects); diarrhea, in 2.9%(1 of 34 subjects); and glans penis ulcer, in 2.9%(1 of 34 subjects). Conclusion: In our hospital, a high rate of capecitabine treatment continuation comparable to that reported in the X-ACT study was obtained, suggesting that capecitabine adjuvant chemotherapy would be well tolerated in clinical practice as well.
要旨
目的: capecitabineはX-ACT試験の結果から結腸癌術後補助化学療法の標準治療の一つとなったが,本邦では忍容性についての報告はほとんどない。今回,治癒切除が行われた結腸癌34例を対象として,capecitabineによる術後補助化学療法8コースの治療継続性や有害事象について後方視的に検討した。結果: capecitabineの8コース完遂率79.4%(27/34例),相対用量強度中央値94.4(13～106)%,相対用量強度60%以上の割合82.4%(28/34例)であり,Grade 3以上の有害事象は手足症候群11.8%(4/34例),口腔粘膜炎2.9%(1/34例),下痢2.9%(1/34例),亀頭部潰瘍2.9%(1/34例)であった。結語: 当院におけるcapecitabineはX-ACT試験と同等の高い治療継続性が得られており,日常診療においても忍容性が高いと考えられた。